Replies to post #2429 on Dendreon Corp fka DNDNQ

[walldiver]

Not formally...but both Mule and Dubinett emphasized that they believed the panel members should be flexible and vote Yes with 9902B stipulation. Witten on Marketwatch just said that FDA was looking for guidance on the survival benefit, and also expects results of 9902B in 2010. To me, this indicates there is no way the FDA will wait for 9902B survival to approve.